BIOMAT Database Logo BIOMAT Database Logo

False-positive amphetamine/ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (CEDIA) and ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (DRI) test results with fenofibrate. 2012

Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
Department of Pharmacology, Clinical Pharmacology, and Toxicology Unit, Izmir Katip Celebi University Faculty of Medicine, Ataturk Training and Research Hospital, Izmir, Turkey. seawise@gmail.com

This case report describes a false-positive amphetamine/ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] and ecstasy (MDMA) screen after therapeutic use of antihyperlipidemic drug, fenofibrate. A 60-year-old male patient was admitted to inpatient psychiatry unit with the diagnosis of alcohol dependency. He was prescribed diazepam 30 mg/day, thiamine 300 mg/day, and naltrexone 50 mg/day. He had also been using fenofibrate 267 mg/day for 3 years for hyperlipidemia and trazodone 100 mg/day for 5 months for insomnia. On routine, urine drugs-of-abuse screening amphetamine/MDMA (CEDIA) test was positive for 4 different occasions and MDMA (DRI) test was positive on 5 different occasions. Gas chromatography/mass spectrometry confirmation of the first positive 3 samples were negative for amphetamine and MDMA. After discontinuation of fenofibrate, amphetamine/MDMA, and MDMA immunoassay results turned out to be negative. Caution should be given to interpretation of amphetamine/MDMA (CEDIA) and MDMA (DRI) tests in patients taking fenofibrate. Specific confirmation with a suitable method should be used to prevent erroneous interpretations.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D008297 Male Males
D008401 Gas Chromatography-Mass Spectrometry A microanalytical technique combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determinations of compounds. Chromatography, Gas-Liquid-Mass Spectrometry,Chromatography, Gas-Mass Spectrometry,GCMS,Spectrometry, Mass-Gas Chromatography,Spectrum Analysis, Mass-Gas Chromatography,Gas-Liquid Chromatography-Mass Spectrometry,Mass Spectrometry-Gas Chromatography,Chromatography, Gas Liquid Mass Spectrometry,Chromatography, Gas Mass Spectrometry,Chromatography, Mass Spectrometry-Gas,Chromatography-Mass Spectrometry, Gas,Chromatography-Mass Spectrometry, Gas-Liquid,Gas Chromatography Mass Spectrometry,Gas Liquid Chromatography Mass Spectrometry,Mass Spectrometry Gas Chromatography,Spectrometries, Mass-Gas Chromatography,Spectrometry, Gas Chromatography-Mass,Spectrometry, Gas-Liquid Chromatography-Mass,Spectrometry, Mass Gas Chromatography,Spectrometry-Gas Chromatography, Mass,Spectrum Analysis, Mass Gas Chromatography
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011345 Fenofibrate An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood. Procetofen,Antara Micronized Procetofen,Apo-Feno-Micro,Apo-Fenofibrate,CiL,Controlip,Fenobeta,Fenofanton,Fenofibrat AL,Fenofibrat AZU,Fenofibrat AbZ,Fenofibrat FPh,Fenofibrat Heumann,Fenofibrat Hexal,Fenofibrat Stada,Fenofibrat-ratiopharm,Fénofibrate Debat,Fénofibrate MSD,Gen-Fenofibrate,LF-178,Lipanthyl,Lipantil,Liparison,Lipidil,Lipidil-Ter,Livesan,Lofibra,MTW-Fenofibrat,Normalip,Novo-Fenofibrate,Nu-Fenofibrate,PMS-Fenofibrate Micro,Phenofibrate,Procetofene,Secalip,Supralip,Tricor,durafenat,fenofibrat von ct,AZU, Fenofibrat,Apo Feno Micro,Apo Fenofibrate,Debat, Fénofibrate,Fenofibrat ratiopharm,Gen Fenofibrate,Heumann, Fenofibrat,Hexal, Fenofibrat,LF 178,LF178,Lipidil Ter,MTW Fenofibrat,Micronized Procetofen, Antara,Novo Fenofibrate,Nu Fenofibrate,PMS Fenofibrate Micro,Procetofen, Antara Micronized,Stada, Fenofibrat
D005189 False Positive Reactions Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Positive Reaction,Positive Reaction, False,Positive Reactions, False,Reaction, False Positive,Reactions, False Positive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000662 Amphetamines Analogs or derivatives of AMPHETAMINE. Many are sympathomimetics and central nervous system stimulators causing excitation, vasopressin, bronchodilation, and to varying degrees, anorexia, analepsis, nasal decongestion, and some smooth muscle relaxation.
D015813 Substance Abuse Detection Detection of drugs that have been abused, overused, or misused, including legal and illegal drugs. Urine screening is the usual method of detection. Drug Abuse Testing,Illicit Drug Testing,Street Drug Testing,Substance Abuse Testing,Drug Abuse Detection,Drug Abuse Screening,Illicit Drug Detection,Street Drug Detection,Detection, Drug Abuse,Detection, Illicit Drug,Detection, Street Drug,Detection, Substance Abuse,Detections, Drug Abuse,Detections, Illicit Drug,Detections, Street Drug,Detections, Substance Abuse,Drug Abuse Detections,Drug Abuse Screenings,Drug Abuse Testings,Drug Testing, Illicit,Drug Testings, Illicit,Illicit Drug Detections,Illicit Drug Testings,Screening, Drug Abuse,Screenings, Drug Abuse,Street Drug Detections,Street Drug Testings,Substance Abuse Detections,Substance Abuse Testings,Testing, Drug Abuse,Testing, Illicit Drug,Testing, Street Drug,Testing, Substance Abuse,Testings, Drug Abuse,Testings, Illicit Drug,Testings, Street Drug,Testings, Substance Abuse

Related Publications

Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
Ecstasy: 3,4-methylenedioxymethamphetamine (MDMA).
February 1998, Acta crystallographica. Section C, Crystal structure communications,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
August 1996, Drug safety,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment.
November 2001, Journal of forensic sciences,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
[Clinical and toxicological evaluation of fatal poisoning with amphetamine derivative--MDMA, ecstasy (3,4-methylenedioxymethamphetamine)].
January 2004, Przeglad lekarski,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") and associated hypoglycemia.
March 1997, The American journal of emergency medicine,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
January 1990, Journal of neurochemistry,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
Comparison and evaluation of DRI methamphetamine, DRI ecstasy, Abuscreen ONLINE amphetamine, and a modified Abuscreen ONLINE amphetamine screening immunoassays for the detection of amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) in human urine.
January 2003, Journal of analytical toxicology,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
3,4-Methylenedioxymethamphetamine (MDMA) and other amphetamine derivatives.
March 1988, Journal of forensic sciences,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion.
July 2002, QJM : monthly journal of the Association of Physicians,
Yusuf Cem Kaplan, and Almla Erol, and Barş Karadaş
Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
December 1988, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!